Journal
JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH
Volume 21, Issue 8, Pages 798-805Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10286020.2018.1505873
Keywords
Non-alcoholic fatty liver disease; curcumin; clinical trial; dyslipidemia
Funding
- Gastroenterology and Hepatology Clinic of the Shaheed Baghaee Hospital (Ahvaz, Iran)
- Indena SpA (Milan, Italy)
Ask authors/readers for more resources
Curcumin is a safe and dietary phytochemical that can improve different pathophysiologic features of non-alcoholic fatty liver disease (NAFLD). Here, we investigated the efficacy of phospholipidated curcumin supplementation in NAFLD patients. In this single-arm study, 36 patients were recruited. Each patient received three capsules a day (each containing 500 mg of phospholipidated curcumin [overall content of curcuminoids per capsule: 100 mg]) for a period of 8 weeks. The results indicated that phospholipidated curcumin supplementation reduced NAFLD severity and ameliorated ultrasonographic and biochemical measures (including liver transaminases and lipid profile) associated with disease progression. [GRAPHICS] .
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available